Ginkgo bioworks reports first quarter 2025 financial results

Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target ginkgo and partners awarded $29 million contract by arpa-h to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems boston , may 6, 2025 /prnewswire/ -- ginkgo bioworks holdings, inc. (nyse: dna, "ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced its results for the first quarter ended march 31, 2025. the update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com.
DNA Ratings Summary
DNA Quant Ranking